Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APL-5125
- Development stage
- Phase 2
- Lead developer
- Apollo Therapeutics
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
APL-5125 is an orally bioavailable small molecule kinase inhibitor developed by Apollo Therapeutics for the treatment of advanced solid tumors, including gastrointestinal cancers such as colorectal carcinoma, cholangiocarcinoma, and appendiceal adenocarcinoma. It acts by inhibiting the Wnt signaling pathway through targeting a kinase—identified in some sources as casein kinase II subunit alpha (CK2a)—thereby preventing Wnt-mediated signaling involved in tumor growth and progression. APL-5125 is currently being evaluated in Phase 1/2 clinical trials for its safety and antitumor activity across a range of solid tumors[1][2][3][4][5].
- Other names
- Wnt signaling inhibitor APL-5125
02
Targets
CK2 (Casein kinase II subunit alpha)
Beyond the preview
Go deeper on APL-5125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APL-5125.